Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Aytu Biopharma Inc
AYTU
Healthcare
Drug Manufacturers - Specialty & Generic
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release...
orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children wi...
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:AYTU)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(11)
•••
Johnthe6
X
Post by
Johnthe6
on Aug 19, 2025 6:08pm
Aytu newest presentation coming up, annual wealth event
Aytu is gonna present at the Annual Wealth Conference in Vancouver on Sep 20, the biggest event with 400+ investors and 30+ companies, check it out https://shorturl.at/zmBW7.
(476)
•••
Iseneschal
X
Post by
Iseneschal
on Jun 06, 2025 1:06pm
AYTU....I'm surprised that this has held up
Even after the P.O announcement On watch No position
(11)
•••
Johnthe6
X
Post by
Johnthe6
on Jun 20, 2024 11:53am
Aytu live streaming
AYTU goes live stream at the conference https://2ly.link/1yXNe
(11)
•••
Johnthe6
X
Post by
Johnthe6
on Jun 17, 2024 1:39pm
aytu new presentation
Aytu BioPharma is going to have a new presentation! It’s free! Free register here: https://buff.ly/4bSLhjm
(11)
•••
Johnthe6
X
Post by
Johnthe6
on Jun 05, 2024 3:21pm
Aytu biopharma presentation on Jun 20
I saw that Aytu is going to give a talk at this virtual event! And it’s free! https://buff.ly/4bSLhjm
(4)
•••
AviseAnalytics
X
Post by
AviseAnalytics
on Nov 28, 2023 7:27am
AYTU BIOPHARMA: LEADING THE ADHD DRUG MARKET
$AYTU Excited to share an article about Aytu BioPharma, Inc. (NASDAQ: AYTU), a pharmaceutical company focused on commercializing novel therapeutics. The Company emphasizes ADHD and pediatric
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 14, 2023 4:17pm
New Press Release - Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
Q1 2024 Adjusted EBITDA of $2.2 millionRx Segment net revenue of $17.8 million and Adjusted EBITDA of $2.4 million in Q1 2024Q1 2024 ADHD net revenue up 31% compared to Q1 2023$20.0 million cash balance at September 30, 2023Company to host conference call today at 4:30pm ETDENVER, CO / ACCESSWIRE...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 08, 2023 8:31am
New Press Release - Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year
Ranked 118th Fastest Growing Company in North AmericaRanked 23rd Fastest Growing Life Sciences CompanyDENVER, CO / ACCESSWIRE / November 8, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 07, 2023 4:17pm
New Press Release - Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023
DENVER, CO / ACCESSWIRE / November 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its first quarter of fiscal year 2024 for the period ended September 30, 2023, after...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 26, 2023 8:02am
New Press Release - Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
U.S. Food & Drug Administration Approval of the Prior Approval Supplement (PAS) Enables Transfer of Cotempla Production to Contract ManufacturerUpon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla XR-ODT, Company Expects to Report Enhanced ADHD Product MarginsDENVER, CO...
read article.
(7)
•••
Securecheck1
X
Comment by
Securecheck1
on Oct 20, 2023 8:12pm
RE:RE:RE:RE:Why is this restricted
You got a point there
(7)
•••
Securecheck1
X
Post by
Securecheck1
on Oct 18, 2023 7:41pm
Stockhouse sucks
It's real easy to get two accounts on Stockhouse but real hard to cancel one. My other account is Patienceiskee.. and if they don't cancel it I'll open a third one and get just as
...more
(7)
•••
Securecheck1
X
Comment by
Securecheck1
on Oct 18, 2023 7:22pm
RE:RE:RE:RE:Why is this restricted
It's really easy to make two accounts but really hard to cancel on stockhouse. It's like I'm talking to myself LOL
(7)
•••
Securecheck1
X
Post by
Securecheck1
on Oct 18, 2023 7:20pm
Hey patiencisky
Hey patience is key. Or whatever. It's really easy to make two accounts on stockhouse BUT really hard to cancel your account isn't it
(7)
•••
Securecheck1
X
Post by
Securecheck1
on Oct 18, 2023 7:06pm
RE:RE:RE:RE:Why is this thing restricted
Another sleazy investor trying to weasel people into his little nest of BBC loving little Susie's
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Featured News Links
A tungsten producer and developer in Portugal, South Korea & Spain on track to become a top supplier
DiagnosTear Announces Clinical Study to Advance Analytical Validation & FDA Submission Pathway of TeaRx(TM)
A Company Focused on Developing Functional Healthier “Better For You” Foods
Building Momentum in One of the World's Most Prospective Copper Regions
Sorrento Resources Provides Update on Exploration on Rodgers Cove Project, Newfoundland